Phenomix Sciences is a Menlo Park, Calif.-based precision medicine biotechnology company that applies data intelligence to obesity treatment through its MyPhenome™ test. MyPhenome equips physicians to tailor treatment plans — including lifestyle and diet intervention, medication, and procedures — by identifying obesity phenotypes such as Hungry Gut, Hungry Brain, and Emotional Hunger. The company raised $7.8M, comprising $5.5M in Series A funding from new investors DexCom and Labcorp (and existing investors including Health2047) plus a $2.3M Phase II SBIR grant from the NIH. Phenomix will use the capital to accelerate commercialization and adoption of MyPhenome in the obesity specialist market and the wider industry, develop and launch additional phenotyping tests, continue supporting clinical studies, and patent novel insights. The NIH SBIR grant specifically funds a prospective study to further validate MyPhenome's accuracy in predicting obesity treatment response. The company also plans to further strategic relationships with pharmaceutical companies and health care providers.

Total raised

$8M

Funding rounds

2

Latest round

Grant

Latest activity

May 2024